Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Schumann

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC PatientsGiorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, et al.
American Journal of Respiratory and Critical Care Medicine|August 13, 2019
Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical TrialDirk-Jan Slebos, Pallav L Shah, Felix J F Herth, et al.
Respiration; International Review of Thoracic Diseases|May 9, 2021
Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe EmphysemaKarin Klooster, Arschang Valipour, Charles-Hugo Marquette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 12, 2020
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2Arschang Valipour, Pallav L Shah, Felix J Herth, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
The Lancet. Oncology|February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLuis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
Nature Communications|March 20, 2021
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infectionLukas Wettstein, Tatjana Weil, Carina Conzelmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Clinical & Experimental Metastasis|July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 12, 2023
Early Detection of Lung Cancer Using Small RNAsTobias Sikosek, Rastislav Horos, Franziska Trudzinski, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC PatientsGiorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, et al.
American Journal of Respiratory and Critical Care Medicine|August 13, 2019
Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical TrialDirk-Jan Slebos, Pallav L Shah, Felix J F Herth, et al.
Respiration; International Review of Thoracic Diseases|May 9, 2021
Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe EmphysemaKarin Klooster, Arschang Valipour, Charles-Hugo Marquette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 12, 2020
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2Arschang Valipour, Pallav L Shah, Felix J Herth, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
The Lancet. Oncology|February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLuis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
Nature Communications|March 20, 2021
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infectionLukas Wettstein, Tatjana Weil, Carina Conzelmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Clinical & Experimental Metastasis|July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 12, 2023
Early Detection of Lung Cancer Using Small RNAsTobias Sikosek, Rastislav Horos, Franziska Trudzinski, et al.
Pageof 11